These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 1905591)

  • 1. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
    Toivonen L; Kadish A; Morady F
    Circulation; 1991 Jul; 84(1):101-8. PubMed ID: 1905591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination anti-arrhythmic drug therapy].
    Lüderitz B; Jung W; Manz M
    Z Kardiol; 1992; 81 Suppl 4():157-61. PubMed ID: 1283933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic drug therapy for sustained ventricular tachycardia.
    Kienzle MG; Williams PD; Zygmont D; Doherty JU; Josephson ME
    Heart Lung; 1984 Nov; 13(6):614-22. PubMed ID: 6149202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy with amiodarone and type I agents for treatment of inducible ventricular tachycardia.
    Jung W; Mletzko R; Manz M; Nitsch J; Lüderitz B
    Pacing Clin Electrophysiol; 1993 Apr; 16(4 Pt 1):778-88. PubMed ID: 7683805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
    Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN
    Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of combination drug therapy with a class IC antiarrhythmic agent and mexiletine for ventricular tachycardia.
    Mendes L; Podrid PJ; Fuchs T; Franklin S
    J Am Coll Cardiol; 1991 May; 17(6):1396-402. PubMed ID: 2016457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic drug combinations in the treatment of ventricular tachycardia.
    Ross DL; Sze DY; Keefe DL; Swerdlow CD; Echt DS; Griffin JC; Winkle RA; Mason JW
    Circulation; 1982 Dec; 66(6):1205-10. PubMed ID: 6814784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: reversing and preventing as different electrophysiological mechanisms.
    Masotti CS; Pierangeli A
    Panminerva Med; 1999 Dec; 41(4):295-306. PubMed ID: 10705709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of combination of IB and IC antiarrhythmics for the treatment of ventricular tachycardia.
    Bleske BE; Kluger J; Fisher J; Chow MS
    J Clin Pharmacol; 1989 Nov; 29(11):998-1002. PubMed ID: 2513339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of antiarrhythmic drugs.
    Lüderitz B; Mletzko R; Jung W; Manz M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S48-52. PubMed ID: 1723119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias.
    Whitford EG; McGovern B; Schoenfeld MH; Garan H; Newell JB; McElroy M; Ruskin JN
    Am Heart J; 1988 Feb; 115(2):360-6. PubMed ID: 3341170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms.
    Rinkenberger RL; Prystowsky EN; Jackman WM; Naccarelli GV; Heger JJ; Zipes DP
    Am Heart J; 1982 Feb; 103(2):177-84. PubMed ID: 6798855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.
    Munsif AN; Saksena S
    Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
    Kus T; Costi P; Dubuc M; Shenasa M
    Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
    Pratt CM; Luck JC; Mann DE; Wyndham CR
    Cardiol Clin; 1984 Feb; 2(1):35-46. PubMed ID: 6443563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of class I and III antiarrhythmic drugs on ventricular tachycardia-interrupting critical paced cycle length with rapid pacing.
    Naitoh N; Washizuka T; Takahashi K; Aizawa Y
    Jpn Circ J; 1998 Apr; 62(4):267-73. PubMed ID: 9583460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans.
    Duff HJ; Mitchell LB; Manyari D; Wyse DG
    J Am Coll Cardiol; 1987 Nov; 10(5):1149-56. PubMed ID: 3668109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.